EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Combined SSTR2-targeted Analogue with 177Lu-DOTATATE radionuclide and octreotide therapy for refractory meningioma: a case report

Carlen A Yuen, Mahbod Jafarvand, David O Kamson, Eleanor Chu, Jennifer E Soun, William H Yong, Frank P Hsu, Hansen Bow, Michelle Zheng, Shyam M Srinivas

Frontiers in Oncology · 11.06.2026 · 16

DOI: 10.3389/fonc.2026.1820428 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 11.06.2026. Verfasst von Carlen A Yuen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Division of Neuro-oncology, University of California, Irvine, Irvine, CA, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Meningiomas are the most common primary intracranial tumor in adults. Beyond surgery and radiation, no standard of care therapy exists. Meningiomas overexpress somatostatin receptor 2 (SSTR2), providing the rationale for somatostatin analogue-based therapies, including octreotide. The addition of everolimus, a mammalian target of rapamycin inhibitor, to octreotide marginally improves the 6-month progression-free survival (PFS) rate. For this reason, novel therapies have emerged for the treatment of refractory meningiomas, including somatostatin receptor targeted radionuclide therapy. However, preliminary results with refractory meningiomas treated with single agent 177 Lu-DOTATATE, a β-emitting peptide receptor radionuclide therapy (PRRT), demonstrated outcomes comparable to those observed with combination octreotide and everolimus. In contrast, in neuroendocrine tumors (NETs), octreotide combined with PRRT has shown significant prolongation of PFS compared to high-dose octreotide alone. The final analysis of the NETTER-1 trial also yielded a trend towards an improvement in median overall survival, supporting the FDA approval of 177 Lu-DOTATATE in 2018 for use in NETs. We present the first case of a refractory meningioma patient treated with combination PRRT and octreotide in a 66-year-old male who received 177 Lu-DOTATATE 7.4 GBq (200 mCi) and intramuscular long-acting octreotide 40 mg every 8 weeks for four cycles followed by a single cycle of octreotide 40 mg monotherapy. Treatment was discontinued due to his unfortunate death from non-treatment related causes, occurring 2.5 months from his final octreotide dose. A 7-week post-treatment MRI brain demonstrated stable disease with 11.5% reduction per RANO-Meningioma and a 2.6% reduction per RECIST 1.1 criteria. Combined PRRT and octreotide represents a promising therapeutic strategy for patients with refractory meningioma.

Schlagwörter

Stichwörter der Autor:innen

177Lu-DOTATATEmeningiomaoctreotidepeptide receptor radionuclide therapy (PRRT)somatostatin receptor type 2 (SSTR2)

Autor:innen und Institutionen

  • Department of Neurology, Division of Neuro-oncology, University of California, Irvine, Irvine, CA, United States.
  • Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA, United States.
  • Department of Radiology, Division of Nuclear Medicine, University of California, Irvine, Irvine, CA, United States.
  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, United States.
  • Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD, United States.
  • Department of Radiology, Division of Neuroradiology, University of California, Irvine, Irvine, CA, United States.

Zitieren

APA

Yuen, C. A., Jafarvand, M., Kamson, D. O., Chu, E., Soun, J. E., Yong, W. H., Hsu, F. P., Bow, H., Zheng, M., & Srinivas, S. M. (2026). Combined SSTR2-targeted Analogue with 177Lu-DOTATATE radionuclide and octreotide therapy for refractory meningioma: a case report. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1820428

Vancouver

Yuen CA, Jafarvand M, Kamson DO, Chu E, Soun JE, Yong WH, et al. Combined SSTR2-targeted Analogue with 177Lu-DOTATATE radionuclide and octreotide therapy for refractory meningioma: a case report. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1820428

BibTeX
@article{Yuen2026,
  author = {Yuen, Carlen A and Jafarvand, Mahbod and Kamson, David O and Chu, Eleanor and Soun, Jennifer E and Yong, William H and Hsu, Frank P and Bow, Hansen and Zheng, Michelle and Srinivas, Shyam M},
  title = {Combined SSTR2-targeted Analogue with 177Lu-DOTATATE radionuclide and octreotide therapy for refractory meningioma: a case report},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1820428}
}
Kostenlos starten →